GM-CSF

University of Zurich Grants Exclusive Worldwide License to Humanigen for the Prevention of GvHD through GM-CSF Neutralization

Jul 23, 2019 | CAR-T, GM-CSF, GvHD

The University of Zurich has granted Humanigen an exclusive license for the prevention of GvHD (Graft-versus-Host Disease) through GM-CSF Neutralization. This deal helps Humanigen expand its extensive intellectual property portfolio to include prevention of...

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

159 WEST BROADWAY SUITE 200
SALT LAKE CITY, UT 84101

University of Zurich Grants Exclusive Worldwide License to Humanigen for the Prevention of GvHD through GM-CSF Neutralization

Pin It on Pinterest